MLC601
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for MLC601, covering 2011-05-02 to 2012-09-28. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine [Phase 2]